Challenges of clinical trial design when there is lack of clinical equipoise: Use of a response-conditional crossover design by Deng, C. (Chunqin) et al.
ORIGINAL COMMUNICATION
Challenges of clinical trial design when there is lack of clinical
equipoise: use of a response-conditional crossover design
Chunqin Deng • Kim Hanna • Vera Bril • Marinos C. Dalakas •
Peter Donofrio • Pieter A. van Doorn • Hans-Peter Hartung •
Ingemar S. J. Merkies
Received: 25 May 2011 / Revised: 18 July 2011 / Accepted: 21 July 2011 / Published online: 7 August 2011
 The Author(s) 2011. This article is published with open access at Springerlink.com
Abstract Clinical equipoise is widely accepted as the
basis of ethics in clinical research and requires investiga-
tors to be uncertain of the relative therapeutic merits of trial
comparators. When clinical equipoise is in question,
innovative trial designs are needed to reduce ethical tension
while satisfying regulators’ requirements. We report a
novel response-conditional crossover study design used in
a Phase 3, randomized, double-blind, placebo-controlled
clinical trial of intravenous 10% caprylate-chromatography
purified immunoglobulin for chronic inflammatory demye-
linating polyradiculoneuropathy. During the initial 24-week
period, patients crossed over to the alternative treatment at
the first sign of deterioration or if they failed to improve or
were unable to maintain improvement at any time after
6 weeks. This trial design addressed concerns about lack of
equipoise raised by physicians interested in trial participa-
tion and proved acceptable to regulatory authorities. The trial
design may be applicable to other studies where clinical
equipoise is in question.
Keywords Clinical equipoise  Crossover trial 
Trial design  Response-conditional  Intravenous
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Introduction
Confirmatory Phase 3 clinical trials typically involve the
demonstration of efficacy and safety of a new intervention
based on comparisons between a treated group and a
control group, which may be placebo or another active
treatment. Guidelines on clinical trial design generally state
that new interventions should be compared with the best
available therapy, and that a placebo comparator should
only be used where no effective treatment exists [1]. This
creates an ethical dilemma and clinical trial design chal-
lenge when regulatory authorities require large-scale, ran-
domised, Phase 3 trials that are placebo controlled (in the
absence of an approved treatment option).
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As an example, intravenous immunoglobulin (IVIg) has
been considered first-line therapy in chronic inflammatory
demyelinating polyradiculoneuropathy (CIDP) for several
years, based on evidence from small trials that IVIg is
beneficial [2]. In the absence of an approved treatment for
CIDP, gaining regulatory approval for the use of IVIg in
CIDP required the conduct of large-scale, placebo-con-
trolled Phase 3 trials.
A randomized, double-blind, controlled design (RCT) is
the gold standard for confirmatory trials. Strengths of the
RCT design include reduction or elimination of patient
selection bias, minimization of imbalance of covariates such
as prognostic factors, and enhanced reliability of statistical
analysis due to the introduction of randomization [3]. Yet the
RCT design also presents methodological and ethical chal-
lenges, including dilemmas in choosing the most suitable
comparator, in ensuring an honest null hypothesis, and in
designing studies that are not only acceptable ethically to
physicians and patients but also meet the rigorous standards
for Phase 3 trials required by regulatory authorities to sup-
port licensure. The latter challenge is the focus of this article
and revolves around the concept of clinical equipoise.
Clinical equipoise
The ethics of clinical research require a state of clinical
equipoise to exist between the comparator treatments.
The term ‘‘clinical equipoise’’ was introduced in 1987 by
Freedman [4], who defined it as a state of genuine uncertainty
on the part of the clinical investigator about the relative
therapeutic merits of the treatment arms in a trial. An inves-
tigator who has good reason to believe that one treatment is
superior is obliged ethically to offer that treatment to patients.
While the results of RCTs invariably show that treatments
differ in their effects, clinical equipoise at the start of a trial
and throughout its duration protects patients from knowingly
being exposed to inferior treatments. Progress in clinical
medicine relies heavily on the willingness of patients to take
part in clinical trials and evidence shows that they are only
willing to participate in RCTs if there is an acknowledgment
of expert uncertainty and if clinical equipoise exists [5].
Without clinical equipoise, investigators may be unwilling
to risk their patients being randomized to a treatment arm (or
placebo) that data indicate may be inferior, while patients are
unlikely to enroll for the same reason.
The ethical debate surrounding clinical equipoise
and RCTs
The principle of clinical equipoise as the basis of clinical
research ethics has come under increasing criticism in
recent years [6–10]. Miller and colleagues argue that
clinical research and therapeutic practice are distinct
activities with different goals, and are governed by dif-
ferent ethical principles [8, 9, 11, 12]. In their view, phy-
sicians in clinical practice have a moral obligation to
provide patients with optimal care, whereas investigators in
clinical trials have a primary duty to increase scientific
knowledge, which may be at the expense of their secondary
duty—to prevent harm to experimental subjects. This view
has been regarded as unsatisfactory by many because it
requires an implausible moral dissociation whereby trial
investigators must ignore the professional obligations that
they have as physicians [13].
The question arises as to whether clinical equipoise can
ever exist in late-stage development trials. Some evidence
for the new treatment under test always exists before a
confirmatory RCT is conducted, including data from in
vitro and animal experiments, data from uncontrolled
clinical studies, evidence for the same treatment in other
diseases, and evidence for similar treatments in the same
disease [14–16]. Clinical equipoise may also be challenged
by the accumulation of data during an RCT. To maintain
clinical equipoise, investigators are usually prevented from
looking at the accumulating data during the study, and an
independent data monitoring committee may be tasked
with stopping or modifying the trial if the accumulating
data indicate that this is necessary. This approach is gen-
erally effective, with the notable exception of situations
where test drugs become identifiable by virtue of having
noticeably different side-effect profiles.
A novel response-conditional crossover trial design
to ease concerns about lack of equipoise
When clinical equipoise is in question, as is undoubtedly
the case with placebo-controlled trials, drug manufacturers
and regulatory bodies share an obligation to utilize clinical
trial designs that remove investigators’ ethical objections
and protect patients while providing the regulators with
appropriate evidence to grant approval. Without this
imperative, there is a risk of patients being denied access to
an effective treatment for a condition where no equivalent
treatment option exists.
Response-adaptive clinical trial designs utilize outcome
data that accumulate as the trial progresses to assign more
patients to the better treatment arm. An alternative novel
approach is to use a response-conditional crossover study
design. This study design was adopted for a randomized,
double-blind, placebo-controlled, pivotal, Phase 3 trial of
10% caprylate-chromatography purified immune globulin
intravenous (IGIV-C; Gamunex, Talecris Biotherapeutics,
Research Triangle Park, NC, USA) for the treatment of
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CIDP [17]. This response-conditional crossover design
differed from a typical crossover design and a response-
adaptive design in a number of ways, as outlined in Table 1.
At the start of the IGIV-C CIDP efficacy (ICE) study,
there was a lack of clinical equipoise. Three of four small,
short-term, placebo-controlled studies had suggested that
IVIg was efficacious in patients with CIDP [2]. Subse-
quently, a meta-analysis concluded that IVIg improved
disability in patients with CIDP for at least 2–6 weeks
compared with placebo, and had similar efficacy to plasma
exchange and oral prednisolone [2]. Furthermore, IVIg was
being used in several countries to treat patients with CIDP
(even though the labelling for IVIg did not include CIDP as
an indication), and IVIg was recommended as a first-line
treatment option for CIDP in clinical practice guidelines
[18–20]. Because of the lack of equipoise, investigators
were unwilling to expose patients to long-term placebo
treatment. Therefore, a trial had to be designed in which
exposure to placebo was minimized.
The prospectively designed, randomized, double-blind,
placebo-controlled ICE study included an initial treatment
period incorporating response-conditional rescue crossover
that is the focus of this paper and an extension phase
(Fig. 1). After screening, patients were randomised in a 1:1
ratio to receive either IGIV-C or placebo. Patients ran-
domized to IGIV-C received a loading dose of 2 g/kg over
2–4 days followed by a maintenance infusion of 1 g/kg
over 1–2 days every 3 weeks for up to 24 weeks. Albumin
(0.1%) was used as the placebo.
During this first period, patients either remained on their
randomized treatment or switched to the alternative treat-
ment depending on their treatment responses [17]. Nonre-
sponders or ‘‘rescued’’ patients received the alternative
treatment for up to 24 weeks and were withdrawn from the
study if no improvement was seen after one infusion of the
alternative treatment or if improvement was not maintained
during the crossover period. Patients who showed main-
tained improvement and completed 24 weeks of treatment
in either the first or crossover periods were eligible for
re-randomization in a blinded 24-week extension phase.
During the extension phase, patients were again withdrawn
from the trial if improvement was not maintained.
This response-conditional crossover trial design enabled
the inclusion of a placebo arm to meet regulatory
requirements, while minimizing ethical concerns about
placebo treatment (the duration of exposure to treatment
was short for any therapy that did not provide sustained
improvement in the patient’s condition) [17]. Importantly,
the design was valid for the primary endpoint: completion
of the first period without crossover (IGIV-C responders
54.2% vs placebo responders 20.7%; p = 0.0002). The
results from the crossover period provided verification of
these findings (IGIV-C 57.8% vs placebo crossover
completers 21.7%; p = 0.005). Overall, the study design
reduced patient exposure to the inferior treatment in favour
of the agent with superior efficacy (see Table 2).
The response-conditional crossover trial design has
some limitations. It requires investigators to be vigilant to
ensure that crossover is applied correctly to avoid patients
remaining on therapy to which they are not responding. In
addition, due to differences in duration of drug exposure,
the safety data need to be adjusted to provide incidences of
adverse events per infusion.
A greater limitation is the reduction in the data that can
be collected during the latter stages of the study, due to
enhanced patient crossover or drop-out (withdrawal). In the
Table 1 A comparison of the response-conditional crossover design with (a) a typical crossover design and (b) a response-adaptive design
Response-conditional crossover design
(a) Typical crossover design
Patients cross over at the end of the first period Patients cross over at any visit so long as the criterion is met
All patients enter the second period Not all patients enter the second period (extension phase)
Patients have a fixed length of exposure (unless they drop out) Patients have different lengths of exposure
Data for the first period and second period are usually analyzed
together with a mixed model
Data for the first period and second period (extension phase) are
analyzed separately
(b) Response-adaptive design
Adaptive design Not an adaptive design
Adaptation depends on the outcome from other patients who have
already been enrolled
Adaptation is ‘‘within-patient’’ and dependent on each patient’s own
response to treatment
Relies on an unblinded group for implementation Does not rely on an unblinded group
Dynamic randomization and unbalanced treatment assignment The initial randomization is preserved and treatment assignment is
balanced
Patients remain in treatment arm to which they were randomized until
primary endpoint
Patients cross over to alternative treatment arm upon non-response
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case of the ICE study, secondary efficacy endpoints
included changes in grip strength and nerve conductions
from baseline to the end of the first period (up to week 24).
The results for these secondary endpoints were supportive
of the results for the primary endpoint, but as patients could
be crossed-over to the alternative therapy at various time
points during the first period, the number of patients pro-
viding data to week 24 was reduced. Furthermore, the
number of patients in the extension phase was reduced
because patients who were crossed over to the alternative
treatment were discontinued if they failed to improve and
maintain improvement based on the adjusted INCAT dis-
ability score.
Despite the limitations discussed above, the response-
conditional crossover trial design appears to provide a
rigorous evaluation of the drug under test. The ICE study
results [17] confirmed the efficacy of IGIV-C in treating
CIDP observed previously [2] and resulted in successful
licensure in the US, Canada, Europe, and elsewhere.
Conclusions
The development of innovative trial designs may help to
ease concern about the lack of clinical equipoise in clinical
trials while providing the clinical trial data required to
support regulatory approvals. In the case of the ICE study,
a novel response-conditional crossover design addressed
concerns about lack of equipoise raised by physicians
interested in trial participation. The design minimized
patient exposure to the inferior treatment and proved
acceptable to both investigators and regulatory authorities.
We conclude that trial sponsors should collaborate with
investigators, experts in the field, and regulatory authorities
Fig. 1 The ICE study—a response-conditional crossover trial design [17]. Reprinted from [17] with permission from Elsevier
Table 2 Treatment exposure in
the ICE study [17]
Treatment group
IGIV-C Placebo
First period
N 59 58
Duration of exposure (weeks), mean (SD) 16.9 (9.0) 10.2 (7.7)
Number of infusions received, mean (SD) 7.2 (3.7) 5.0 (3.7)
Crossover period
N 45 23
Duration of exposure (weeks), mean (SD) 16.5 (9.6) 9.1 (8.7)
Number of infusions received, mean (SD) 7.4 (4.1) 3.9 (2.9)
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at the protocol design stage to ensure that any proposed
study design minimizes ethical concerns regarding lack of
equipoise.
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